WEKO3
アイテム
EGFR阻害薬はHERファミリー特異的T細胞の抗腫瘍効果を増強する
https://asahikawa-med.repo.nii.ac.jp/records/5000
https://asahikawa-med.repo.nii.ac.jp/records/5000b037fa95-9565-4c3d-9afb-01148e5341a8
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
5801.pdf (2.4 MB)
|
|
| Item type | 学位論文 / Thesis or Dissertation_02(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2014-07-03 | |||||
| タイトル | ||||||
| タイトル | EGFR阻害薬はHERファミリー特異的T細胞の抗腫瘍効果を増強する | |||||
| 言語 | ja | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | epidermal growth factor receptor (EGFR) | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | head and neck squamous cell carcinoma (HNSCC) | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | immunotherapy | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | tumour antigens | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | major histocompatibility complex class II | |||||
| キーワード | ||||||
| 主題Scheme | Other | |||||
| 主題 | CD4 helper T lymphocytes | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_db06 | |||||
| 資源タイプ | doctoral thesis | |||||
| アクセス権 | ||||||
| アクセス権 | open access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_abf2 | |||||
| タイトル ローマ字 | ||||||
| その他のタイトル | EGFR inhibitors augment antitumour helper T- cell responses of HER family-specific immunotherapy | |||||
| 著者 |
熊井, 琢美
× 熊井, 琢美 |
|||||
| 著者 ローマ字 | ||||||
| 値 | Kumai, takumi | |||||
| 書誌情報 |
British Journal of Cancer 巻 109, 号 6, p. 2155-2166, 発行日 2013-09-01 |
|||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1038/bjc.2013.577 | |||||
| 識別番号 その他 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | PMID：24045666 | |||||
| 学位授与番号 | ||||||
| 学位授与番号 | 甲463 | |||||
| 学位授与年月日 | ||||||
| 学位授与年月日 | 2014-03-25 | |||||
| 学位名 | ||||||
| 学位名 | 博士(医学） | |||||
| 学位授与機関 | ||||||
| 学位授与機関識別子Scheme | kakenhi | |||||
| 学位授与機関識別子 | 10107 | |||||
| 学位授与機関名 | 旭川医科大学 | |||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | BACKGROUND: \nHead and neck squamous cell carcinoma (HNSCC) is a major cause of cancer-related morbidity and mortality worldwide. Epidermal growth factor receptor (EGFR)-targeted therapy is an attractive strategy alternative to conventional cancer treatments for HNSCC, but its efficacy remains controversial. T-cell-based immunotherapy has been proposed as a novel therapeutic approach to improve the clinical outcome for HNSCC. In this study, we report human epidermal receptor (HER) family epitopes that induced CD4 T-cell responses to HNSCC. The results provide support for a novel strategy to treat HNSCC by combining EGFR-targeted therapy with T-cell-based immunotherapy. METHODS: \nWe evaluated the capacity of predicted CD4 T-cell peptide epitopes from EGFR to induce antitumour immune responses in vitro. In addition, EGFR inhibitors were evaluated for their ability to augment tumour MHC class II expression in HNSCC cell lines and subsequently increase T-cell recognition. RESULTS: \nAmong several predicted peptide epitopes, EGFR875-889 elicited CD4 T-cell responses that were restricted by HLA-DR4, DR15, or DR53 molecules, indicating that the peptide functions as a promiscuous T-cell epitope. The peptide-reactive T cells responded to autologous dendritic cells loaded with EGFR-expressing tumour cell lysates, indicating that these epitopes are naturally processed. In addition, the CD4 T cells were capable of directly recognising and killing HNSCC cells expressing EGFR and the appropriate HLA class II molecule. T cells reactive with the EGFR875-889 epitope could be detected in the blood of HNSCC patients. EGFR875-889-reactive CD4 T cells were also able to recognise several peptide analogues derived from homologous regions of EGFR family members, HER-2, HER-3 and c-MET. Finally, we examined the effects of EGFR tyrosine kinase inhibition or EGFR-blocking antibodies on CD4 T-cell tumour reactivity. Treatment of tumour cells with the EGFR inhibitors enhanced tumour recognition by EGFR875-889-reactive T cells presumably due to the upregulation of HLA-DR expression in the HNSCC cells. CONCLUSION: \nWe identified novel CD4 T-cell EGFR epitopes and amongst these, EGFR875-889 functions as a promiscuous helper T-cell epitope that can elicit effective antitumour T-cell responses against tumours expressing HER family members and c-MET. These observations should facilitate the translation of T-cell-based immunotherapy into the clinic for the treatment of HNSCC and provide a rational basis for EGFR inhibition, immune-targeted combination therapy. |
|||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| フォーマット | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | application/pdf | |||||
